Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

https://ift.tt/zPEl2I3

  

from Sanofi - Aventis Groupe https://ift.tt/qvjxlhr
via IFTTT